# Filing Detail

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001493152-26-010625
Filing Date
2026-03-17
Accepted
2026-03-17 17:28:20
Documents
66
Period of Report
2025-12-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-K | form10-k.htm iXBRL | 10-K | 1067057
2 | EX-23.1 | ex23-1.htm | EX-23.1 | 3021
3 | EX-31.1 | ex31-1.htm | EX-31.1 | 12006
4 | EX-31.2 | ex31-2.htm | EX-31.2 | 12240
5 | EX-32.1 | ex32-1.htm | EX-32.1 | 4805
6 | EX-32.2 | ex32-2.htm | EX-32.2 | 4996
7 | GRAPHIC | form10-k_001.jpg | GRAPHIC | 25328
8 | GRAPHIC | form10-k_002.jpg | GRAPHIC | 21179
9 | GRAPHIC | form10-k_003.jpg | GRAPHIC | 20008
10 | GRAPHIC | form10-k_004.jpg | GRAPHIC | 24049
11 | GRAPHIC | form10-k_005.jpg | GRAPHIC | 30774
12 | GRAPHIC | form10-k_006.jpg | GRAPHIC | 13328
13 | GRAPHIC | form10-k_007.jpg | GRAPHIC | 10452
14 | GRAPHIC | form10-k_008.jpg | GRAPHIC | 52870
15 | GRAPHIC | form10-k_009.jpg | GRAPHIC | 31858
16 | GRAPHIC | fin_001.jpg | GRAPHIC | 63426
| Complete submission text file | 0001493152-26-010625.txt |  | 5673469

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
17 | XBRL SCHEMA FILE | telo-20251231.xsd | EX-101.SCH | 31921
18 | XBRL CALCULATION FILE | telo-20251231_cal.xml | EX-101.CAL | 45666
19 | XBRL DEFINITION FILE | telo-20251231_def.xml | EX-101.DEF | 140778
20 | XBRL LABEL FILE | telo-20251231_lab.xml | EX-101.LAB | 372245
21 | XBRL PRESENTATION FILE | telo-20251231_pre.xml | EX-101.PRE | 289816
69 | EXTRACTED XBRL INSTANCE DOCUMENT | form10-k_htm.xml | XML | 520889

Mailing Address 100 SE 2ND ST SUITE 2000 #1009 MIAMI FL 33131
Business Address 100 SE 2ND ST SUITE 2000 #1009 MIAMI FL 33131 786-396-6723
Telomir Pharmaceuticals, Inc. (Filer) CIK: 0001971532 (see all company filings)

EIN.: 872606031 | State of Incorp.: FL | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-41952 | Film No.: 26763646
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)